-
1
المؤلفون: Rashmi Bagga, Radhika Srinivasan, Shalmoli Bhattacharyya, Shifa Javed
المصدر: Molecular and Cellular Biochemistry. 473:51-62
مصطلحات موضوعية: 0301 basic medicine, Epithelial-Mesenchymal Transition, medicine.medical_treatment, Clinical Biochemistry, Cell, Uterine Cervical Neoplasms, Biology, 03 medical and health sciences, 0302 clinical medicine, Cancer stem cell, Cell Line, Tumor, Gene expression, medicine, Humans, Insulin-Like Growth Factor I, Molecular Biology, Cisplatin, Cervical cancer, Growth factor, Cell Biology, General Medicine, medicine.disease, Neoplasm Proteins, 030104 developmental biology, medicine.anatomical_structure, Apoptosis, Cell culture, 030220 oncology & carcinogenesis, Neoplastic Stem Cells, Cancer research, Female, Signal Transduction, medicine.drug
الوصف: Cancer stem cells (CSC) drive tumour progression and are implicated in relapse and resistance to conventional cancer therapies. Identification of differentially expressed genes by gene expression (GEP) profiling may help identify the differentially activated signalling pathways in cancer stem cells as opposed to bulk tumour cells which will provide new insights into cancer stem cell biology and aid in identification of novel therapeutic targets. Our study focused on the inhibition of CSC from cervical cancer cell lines by targeting insulin-like growth factor (IGF), which was identified by differential GEP. Targeted inhibition of IGF-1 by JB-1 trifluoroacetate (inhibitor of IGF) was carried out in SiHa, RSBS-14 and RSBS-43 cervical cancer derived cell lines. Effect of cisplatin was also evaluated. Inhibition of IGF-1 signalling was confirmed by demonstration of reduction in p-Akt levels. The cell biological effects of IGF-1 inhibition included an increase in G2M/S fraction, increased apoptosis and decreased invasive ability. JB-1 and cisplatin showed synergism. However, transcript levels of stemness and EMT markers showed variable levels following IGF inhibition. Overall, this proof-of-concept study has shown that IGF-1 is an attractive target for inhibition of CSC in invasive cervical cancer.
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::619fe4a597bb20186cf48bf314ac728cTest
https://doi.org/10.1007/s11010-020-03807-6Test -
2
المصدر: Journal of Cancer Research and Therapeutics, Vol 14, Iss 5, Pp 977-982 (2018)
مصطلحات موضوعية: 0301 basic medicine, Adult, Male, Pathology, medicine.medical_specialty, renal cell carcinoma, medicine.medical_treatment, SPOP, urologic and male genital diseases, lcsh:RC254-282, 03 medical and health sciences, 0302 clinical medicine, Renal cell carcinoma, Biomarkers, Tumor, Medicine, Humans, Radiology, Nuclear Medicine and imaging, Carcinoma, Renal Cell, Tumor marker, mammalian target of rapamycin, Aged, Kidney, business.industry, Cancer, Nuclear Proteins, Kidney Neoplasm, General Medicine, Biomarker, Middle Aged, medicine.disease, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Nephrectomy, female genital diseases and pregnancy complications, speckle-type POZ protein, Gene Expression Regulation, Neoplastic, Repressor Proteins, 030104 developmental biology, medicine.anatomical_structure, Oncology, 030220 oncology & carcinogenesis, Biomarker (medicine), Female, business
الوصف: Background: Renal cell carcinoma (RCC) is the most common kidney neoplasm and requires an early diagnosis because of poor response to conventional cancer treatments. However, till date, there is no reliable tumor marker available for the diagnosis of RCC. Objective: The aim of the study was to evaluate the expression of speckle-type POZ protein (SPOP) as a biomarker in patients with RCC. Materials and Methods: Blood samples were collected from fifty patients with RCC and ten healthy controls. Tumor tissue samples were obtained from nephrectomy specimen. Adjoining normal renal parenchyma of these fifty patients and eight normal renal tissue samples from normal kidney served as controls. Reverse transcriptase-polymerase chain reaction assay was performed for SPOP and mammalian target of rapamycin expression. Results: SPOP was significantly increased in blood of patients with RCC as compared to controls (0.754 ± 0.32 vs. 0.224 ± 0.14; P < 0.001). Twenty-two patients (44%) had SPOP value more than mean + 2 standard deviation (SD) of controls. In RCC tissue, 42 (84%) patients had increased expression of SPOP more than 0.523 (mean + 2 SD value of SPOP expression in controls). SPOP expression was high in blood of 60% patients and in tumor tissue of 90% patients with clear cell RCC. SPOP was higher in high grade and high stage of RCC. Conclusions: Our result suggests that SPOP expression in blood might have a sensitivity that is low for routine diagnostic use and for screening for RCC. However, SPOP could be a potential tissue diagnostic biomarker in RCC.
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fe30990fca4413570cdc5e39d6f65d0aTest
https://pubmed.ncbi.nlm.nih.gov/30197334Test
